Causal associations of autoimmune thyroiditis and papillary thyroid carcinoma: mRNA expression of selected nuclear receptors and other molecular targets

Macejova,Dana; Podoba,Jan; Toporova,Lucia; Grigerova,Marianna; Kajo,Karol; Machalekova,Katarina; Brtko,Julius

doi:10.3892/ol.2019.10770

Causal associations of autoimmune thyroiditis and papillary thyroid carcinoma: mRNA expression of selected nuclear receptors and other molecular targets

Authors:
- Dana Macejova
- Jan Podoba
- Lucia Toporova
- Marianna Grigerova
- Karol Kajo
- Katarina Machalekova
- Julius Brtko
View Affiliations

Affiliations: Department of Endocrine Regulations and Psychopharmacology, Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, 845 05 Bratislava, Slovak Republic, Department of Endocrinology, Slovak Medical University and St. Elisabeth Cancer Institute, 812 50 Bratislava, Slovak Republic, Department of Pathology, Slovak Medical University and St. Elisabeth Cancer Institute, 812 50 Bratislava, Slovak Republic
Published online on: August 22, 2019 https://doi.org/10.3892/ol.2019.10770
Pages: 4270-4277

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Potential causal associations of autoimmune thyroiditis (AIT) and papillary thyroid carcinoma (PTC) have been studied previously. The mRNA expression patterns of thyroid hormone receptors (TR), retinoid receptors (RAR), rexinoid receptors (RXR), dihydroxyvitamin D3 receptors (VDR), and progesterone receptors (PR) in PTC tissue of patients without autoimmune thyroiditis (PTC/AIT‑) and in PTC tissue of patients with coexisting AIT (PTC/AIT+) have been investigated in order to judge whether the observed changes may take part in the promotion and progression of thyroid cancer. Tumours with or without AIT were classified histologically and the semiquantitative PCR was performed. The results revealed that there was decreased expression of TRα, TRβα, RARα and PR mRNA in PTC/AIT+ tumours when compared with PTC/AIT‑ tumours. Decreased expression of RARα in PTC/AIT+ was detected when compared with PTC/AIT‑ patients. A similar effect of AIT was observed with a decrease in RARγ expression in PTC/AIT+ patients. On the other hand, there was an increased expression of VDR in thyroid tumours (PTC/AIT+) when compared with PTC/AIT‑. PR mRNA was decreased in the thyroid tumours of PTC/AIT+ patients when compared with PTC/AIT‑ patients. In addition, there was an increased expression of MKi67 and complement C3 in PTC of PTC/AIT+ when compared with PTC/AIT‑. In the PTC/AIT+ group, a decreased level of IGF‑1 mRNA was found when compared with the PTC/AIT‑ group. According to the significant differences of the studied markers in PTC/AIT+ compared with PTC/AIT‑, it was indicated that AIT may be a predisposing factor for the development of PTC.

View Figures

View References

1	Bozec A, Lassalle S, Hofman V, Ilie M, Santini J and Hofman P: The thyroid gland: A crossroad in inflammation-induced carcinoma? An ongoing debate with new therapeutic potential. Curr Med Chem. 17:3449–3461. 2010. View Article : Google Scholar : PubMed/NCBI
2	Muzza M, Degl'Innocenti D, Colombo C, Perrino M, Ravasi E, Rossi S, Cirello V, Beck-Peccoz P, Borrello MG and Fugazzola L: The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: Clinical and molecular studies. Clin Endocrinol (Oxf). 72:702–708. 2010. View Article : Google Scholar : PubMed/NCBI
3	Babli S, Payne RJ, Mitmaker E and Rivera J: Effects of chronic lymphocytic thyroiditis on the clinicopathological features of papillary thyroid cancer. Eur Thyroid J. 7:95–101. 2018. View Article : Google Scholar : PubMed/NCBI
4	Ott RA, Calandra DB, McCall A, Shah KH, Lawrence AM and Paloyan E: The incidence of thyroid carcinoma in patients with Hashimoto's thyroiditis and solitary cold nodules. Surgery. 98:1202–1206. 1985.PubMed/NCBI
5	Schäffer A, Palitzsch KD, Seiffarth C, Hohne HM, Riedhammer FJ, Hofstädter F, Schölmerich J and Rüschoff J: Coexistent thyroiditis is associated with lower tumour stage in thyroid carcinoma. Eur J Clin Invest. 28:838–844. 1998. View Article : Google Scholar : PubMed/NCBI
6	Loh KCH, Greenspan FS, Dong F, Miller TR and Yeo PPB: Influence of lymphocytic thyroiditis on the prognostic outcome of patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 84:458–463. 1999. View Article : Google Scholar : PubMed/NCBI
7	Shih ML, Lee JA, Hsieh CB, Yu JC, Liu HD, Kebebew E, Clark OH and Duh QY: Thyroidectomy for Hashimoto's thyroiditis: Complications and associated cancers. Thyroid. 18:729–734. 2008. View Article : Google Scholar : PubMed/NCBI
8	Fiore E, Rago T, Latrofa F, Provenzale MA, Piaggi P, Delitala A, Scutari M, Basolo F, Di Coscio G, Grasso L, et al: Hashimoto's thyroiditis is associated with papillary thyroid carcinoma: Role of TSH and of treatment with L-thyroxine. Endocr Relat Cancer. 18:429–437. 2011. View Article : Google Scholar : PubMed/NCBI
9	Vaccarella S, Franceschi S, Bray F, Wild CP, Plummer M and Dal Maso L: Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis. N Engl J Med. 7:614–617. 2016. View Article : Google Scholar
10	Antonaci A, Consorti F, Mardente S and Giovannone G: Clinical and biological relationship between chronic lymphocytic thyroiditis and papillary thyroid carcinoma. Oncol Res. 17:495–503. 2009. View Article : Google Scholar : PubMed/NCBI
11	Prescott SM and Fitzpatrick FA: Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta. 1470:M69–M78. 2000.PubMed/NCBI
12	Cornetta A, Russell JP, Cunnane M, Keane WM and Rothstein JL: Cyclooxygenase-2 expression in human thyroid carcinoma and Hashimoto's thyroiditis. Laryngoscope. 112:238–242. 2002. View Article : Google Scholar : PubMed/NCBI
13	Schmidt JA, Allen NE, Almquist M, Franceschi S, Rinaldi S, Tipper SJ, Tsilidis KK, Weiderpass E, Overvad K, Tjønneland A, et al: Insulin-like growth factor-i and risk of differentiated thyroid carcinoma in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev. 23:976–985. 2014. View Article : Google Scholar : PubMed/NCBI
14	Yu J, Mai W, Ciu Y and Kong L: Key genes and pathways predicted in papillary thyroid carcinoma based on bioinformatics analysis. J Endocrinol Invest. 39:1285–1293. 2016. View Article : Google Scholar : PubMed/NCBI
15	Eldien MMS, Abdou AG, Rageh T, Abdelrazek E and Elkholy E: Immunohistochemical expression of ER-α and PR in papillary thyroid carcinoma. Ecancermedicalscience. 11:7482017. View Article : Google Scholar : PubMed/NCBI
16	Brierley JD, Gospodarowicz MK and Wittekind C: TNM classification of malignant tumours8th. Oxford: Wiley Blackwell. ISBN 9781119263579. 2017
17	Brtko J, Sejnová D, Ondková S and Macejová D: Malignant Triton tumour exhibits a complete expression pattern of nuclear retinoid and rexinoid receptor subtypes. Gen Physiol Biophys. 28:425–427. 2009. View Article : Google Scholar : PubMed/NCBI
18	Macejová D, Galbavý S, Podoba J, Bialešová L and Brtko J: mRNA expression pattern of retinoic acid and retinoid X nuclear receptor subtypes in human thyroid papillary carcinoma. Oncol Rep. 30:2371–2378. 2013. View Article : Google Scholar : PubMed/NCBI
19	Franceschi S, Boyle P, Maisonneuve P, La Vecchia C, Burt AD, Kerr DJ and MacFarlane GJ: The epidemiology of thyroid carcinoma. Crit Rev Oncog. 4:25–52. 1993.PubMed/NCBI
20	Lai X, Xia Y, Zhang B, Li J and Jiang Y: A meta-analysis of Hashimoto's thyroiditis and papillary thyroid carcinoma risk. Oncotarget. 8:62414–62424. 2017. View Article : Google Scholar : PubMed/NCBI
21	Paolieri F, Salmaso C, Battifora M, Montagna P, Pesce G, Bagnasco M, Richiusa P, Galluzzo A and Giordano C: Possible pathogenetic relevance of interleukin-1 beta in ‘destructive’ organ-specific autoimmune disease (Hashimoto's thyroiditis). Ann N Y Acad Sci. 876:221–228. 1999. View Article : Google Scholar : PubMed/NCBI
22	Liu L and Gudas LJ: Retinoic acid induces expression of the interleukin-1beta gene in cultured normal human mammary epithelial cells and in human breast carcinoma lines. J Cell Physiol. 193:244–252. 2002. View Article : Google Scholar : PubMed/NCBI
23	Ciampolillo A, De Tullio C and Giorgino F: The IGF-I/IGF-I receptor pathway: Implications in the pathophysiology of thyroid cancer. Curr Med Chem. 12:2881–2891. 2005. View Article : Google Scholar : PubMed/NCBI
24	Surmacz E and Bartucci M: Role of estrogen receptor alpha in modulating IGF-I receptor signaling and function in breast cancer. J Exp Clin Cancer Res. 23:385–394. 2004.PubMed/NCBI
25	Garcia-Solis P and Aceves C: 5′Deiodinase in two breast cancer cell lines: Effect of triiodothyronine, isoproterenol and retinoids. Mol Cell Endocrinol. 201:25–31. 2003. View Article : Google Scholar : PubMed/NCBI
26	Dhiman VK, Bolt MJ and White KP: Nuclear receptors in cancer-uncovering new and evolving roles through genomic analysis. Nat Rev Genet. 19:160–174. 2018. View Article : Google Scholar : PubMed/NCBI
27	Kim WG and Cheng SY: Thyroid hormone receptors and cancer. Biochim Biophys Acta. 1830:3928–3936. 2013. View Article : Google Scholar : PubMed/NCBI
28	Nugroho J and Schweiger B: Isotretinoin as a possible environmental trigger to autoimmunity in genetically susceptible patients. Case Rep Pediatr. 2017:42076562017.PubMed/NCBI
29	Schmutzler C, Brtko J, Winzer R, Jakobs TC, Meissner-Weigl J, Simon D, Goretzki PE and Köhrle J: Functional retinoid and thyroid hormone receptors in human thyroid-carcinoma cell lines and tissues. Int J Cancer. 76:368–376. 1998. View Article : Google Scholar : PubMed/NCBI
30	Hoftijzer HC, Liu YY, Morreau H, van Wezel T, Pereira AM, Corssmit EP, Romijn JA and Smit JW: Retinoic acid receptor and retinoid X receptor subtype expression for the differential diagnosis of thyroid neoplasms. Eur J Endocrinol. 160:631–638. 2009. View Article : Google Scholar : PubMed/NCBI
31	Haugen BR, Larson LL, Pugazhenthi U, Hays WR, Klopper JP, Kramer CA and Sharma V: Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids. J Clin Endocrinol Metab. 89:272–280. 2004. View Article : Google Scholar : PubMed/NCBI
32	Kim D: The role of vitamin D in thyroid diseases. Int J Mol Sci. 18(pii): E19492017. View Article : Google Scholar : PubMed/NCBI
33	Casula S and Bianco AC: Thyroid hormone deiodinases and cancer. Front Endocrinol (Lausanne). 3:742012. View Article : Google Scholar : PubMed/NCBI
34	Chen W, Wang S, Tian T, Bai J, Hu Z, Xu Y, Dong J, Chen F, Wang X and Shen H: Phenotypes and genotypes of insulin-like growth factor 1, IGF-binding protein-3 and cancer risk: Evidence from 96 studies. Eur J Hum Genet. 17:1668–1675. 2009. View Article : Google Scholar : PubMed/NCBI
35	Lin K, He S, He L, Chen J, Cheng X, Zhang G and Zhu B: Complement component 3 is a prognostic factor of non-small cell lung cancer. Mol Med Rep. 10:811–817. 2014. View Article : Google Scholar : PubMed/NCBI